Galectin-3 expression is prognostic in diffuse type gastric adenocarcinoma, confers aggressive phenotype, and can be targeted by YAP1/BET inhibitors

BACKGROUND: Overexpression of Galectin-3 (Gal-3), a β-galactoside binding protein, has been noted in many tumour types but its functional significance and clinical utility in gastric adenocarcinoma (GAC) are not well known. METHODS: We studied 184 GAC patients characterised by histologic grade, sub-...

Descripción completa

Detalles Bibliográficos
Autores principales: Ajani, Jaffer A, Estrella, Jeannelyn S, Chen, Qiongrong, Correa, Arlene M, Ma, Lang, Scott, Ailing W, Jin, Jiankang, Liu, Bin, Xie, Min, Sudo, Kazuki, Shiozaki, Hironori, Badgwell, Brian, Weston, Brian, Lee, Jeffrey H, Bhutani, Manoop S, Onodera, Hisashi, Suzuki, Koyu, Suzuki, Akihiro, Ding, Sheng, Hofstetter, Wayne L, Johnson, Randy L, Bresalier, Robert S, Song, Shumei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2018
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765229/
https://www.ncbi.nlm.nih.gov/pubmed/29136404
http://dx.doi.org/10.1038/bjc.2017.388

Ejemplares similares

Ejemplares similares